Topical Delivery of Cultured Stem Cells to Human Non-Healing Wounds: GMP Facility Development in an Academic Setting and FDA Requirements for an IND and Human Testing

Author(s): Tatyana Yufit, Polly Carson, Vincent Falanga

Journal Name: Current Drug Delivery

Volume 11 , Issue 5 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


With increasing emphasis on translational research, the need for appropriate regulatory oversight and approval has become essential. The requirements of the Food and Drug Administration (FDA) for Investigational New Drug (IND) exemption in studies that are investigator-initiated have become increasingly stringent. Moreover, academic institutions have not had substantial experience in establishing Good Manufacturing Practice (GMP) facilities required for manipulating human cells in vitro and for chemical or biochemical manufacturing. GMP regulations are established by the FDA under the authority of the Federal Food, Drug and Cosmetic Act. In this report, the authors outline the general strategy and some critical steps that an investigator and the institution may find helpful in developing a GMP facility, especially in an academic center. Also, more specifically and as proof of principle, we describe our approach to culturing autologous bone marrow-derived human mesenchymal stem cells (MSCs) and delivering them to non healing wounds. The lessons learned in this often lengthy and challenging process may be helpful to other academic institutions and investigators embarking on manipulating and delivering viable cells for human experimentation.

Keywords: Food and Drug Administration (FDA), Good Manufacturing Practice (GMP), Investigational New Drug (IND), Mesenchymal Stem Cells (MSCs), Quality Assurance (QA), Quality Control (QC).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [572 - 581]
Pages: 10
DOI: 10.2174/15672018113109990035
Price: $65

Article Metrics

PDF: 35